Benefit of active treatment in non-small-cell lung cancer in elderly patients and patients with poor performance status

Clinical Lung Cancer

Volumn 5, Issue 2, 2003, Pages 86-89

  Lee, David ^a   Belani, Chandra P ^a   Salgia, Ravi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELDERLY CARE; FATIGUE; HEALTH STATUS; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; RADIATION DOSE; SURVIVAL RATE;

EID: 0242320431     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70325-4     Document Type: Article

References (13)

1. Gridelli C, Maione P, Barletta E. Individualized chemotherapy for elderly patients with nonsmall-cell lung cancer. Curr Opin Oncol 2002; 14:199-203.
2. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 2001; 8:1-25.
3. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067.
4. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001; 19:1064-1070.
5. Maguire J, Kelly V, Smith N, et al. Chemotherapy and radical radiotherapy for patients with inoperable NSCLC aged 70 or over - results of a treatment policy based on performance status and stage at presentation. Lung Cancer 2003; 41(suppl 2):S19 (Abstract #O-54).
6. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined modality therapy for non-small-cell lung cancer (NSCLC) in the elderly. Lung Cancer 2003; 41(suppl 2):S19 (Abstract #O-55).
7. Leong SS, Foo KF, Tay MH, et al. A randomized phase II trial of gemcitabine, vinorelbine or docetaxel in the treatment of elderly and/or poor performance state patients with non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41(suppl 2):S18-S19 (Abstract #O-53).
8. Langer CJ , Stephenson P, Schiller J, et al. ECOG 1599: randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC. Lung Cancer 2003; 41(suppl 2):S18 (Abstract #O-52).
9. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs.) with NSCLC do as well as younger patients (<70). Lung Cancer 2003; 41(suppl 2):S17 (Abstract #O-49).
10. Belani CP, Fossella FV, on behalf of the TAX 326 Study Group. Phase III study (TAX 326) of docetaxelcisplatin (DC) and docetaxel-carboplatin (DCB) versus vinorelbine-cisplatin (VC) for the First-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC): analyses in elderly patients. Lung Cancer 2003; 41(suppl 2):S18 (Abstract #O-51).
11. Schild SE, Stella PJ, Geyer SM, et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54:370-378.
12. Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic non-small-cell lung carcinoma. Cancer 2001; 92:2639-2647.
13. Fossella FV, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 2003; 21:3016-3024.